[Federal Register Volume 67, Number 69 (Wednesday, April 10, 2002)]
[Notices]
[Page 17417]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-8675]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Availability for Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Patent Application Concerning Chimeric Filovirus 
Glycoprotein

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the 
availability for licensing of U.S. Patent Application No. 10/066,506 
entitled ``Chimeric Filovirus Glycoprotein'' filed January 31, 2002. 
The United States Government as represented by the Secretary of the 
Army has rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, Maryland 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research & Technology Assessment, (301) 619-6664, both 
at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: Chimeric GP molecules were constructed which 
contain portions of both the EBOV and MBGV GP proteins by swapping the 
subunits between EBOV and MBGV. The chimeric molecules were cloned into 
an alphavirus replicon, which offers the advantage of high protein 
expression levels in mammalian cells and is a proven vaccine vector. 
These chimeric molecules fully protected guinea pigs from MBGV 
challenge, and conversely protected the animals from EBOV challenge. 
These results indicate that a protective epitope resides within the GP2 
subunit of the MBGV GP protein and at least partially within the GP2 
subunit of the EBOV GP protein. Additionally these results show that a 
construction of a single-component bivalent vaccine protective in 
guinea pigs is achievable.

Luz D. Ortiz,
Army Federal Register Liaison Officer.
[FR Doc. 02-8675 Filed 4-9-02; 8:45 am]
BILLING CODE 3710-08-M